Reciprocal and Autonomous Glucocorticoid and Androgen Receptor Activation in Salivary Duct Carcinoma.


Journal

Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500

Informations de publication

Date de publication:
01 03 2020
Historique:
received: 15 05 2019
revised: 01 10 2019
accepted: 22 11 2019
pubmed: 28 11 2019
medline: 5 1 2021
entrez: 28 11 2019
Statut: ppublish

Résumé

To determine the expression of glucocorticoid receptor (GR) and androgen receptor (AR) in salivary duct carcinoma (SDC) and to analyze the role of these proteins in the development and management of this disease entity. We performed a phenotypic assessment of GR and AR localization and expression, and determined their association with clinicopathologic factors in 67 primary SDCs. Of the 67 primary tumors, 12 (18%) overexpressed GR protein, 30 (45%) had constitutive expression, and 25 (37%) had complete loss of expression. Reciprocal GR and AR expression was found in 32 (48%) tumors, concurrent constitutive GR and AR expression in 23 (34%), and simultaneous loss of both receptors and high GR with AR expressions were found in 12 (18%). GR overexpression was significantly associated with worse clinical outcomes. Our study, for the first time, demonstrates differential GR and AR expressions, autonomous GR and AR activation, and ligand-independent AR expression and activation in SDC cells. The findings provide critical information on the roles of GR and AR steroid receptors in SDC tumorigenesis and development of biomarkers to guide targeted steroid receptor therapy trials in patients with these tumors.

Identifiants

pubmed: 31772120
pii: 1078-0432.CCR-19-1603
doi: 10.1158/1078-0432.CCR-19-1603
pmc: PMC7056500
mid: NIHMS1544917
doi:

Substances chimiques

AR protein, human 0
Antineoplastic Agents, Hormonal 0
Benzamides 0
Biomarkers, Tumor 0
Hormone Antagonists 0
Nitriles 0
Receptors, Androgen 0
Receptors, Glucocorticoid 0
Phenylthiohydantoin 2010-15-3
Mifepristone 320T6RNW1F
enzalutamide 93T0T9GKNU

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1175-1184

Subventions

Organisme : NIDCR NIH HHS
ID : HHSN268200900039C
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Organisme : NIDCR NIH HHS
ID : U01 DE019765
Pays : United States

Informations de copyright

©2019 American Association for Cancer Research.

Références

Cancer. 2018 Sep 15;124(18):3693-3705
pubmed: 30289966
Ann N Y Acad Sci. 2004 Jun;1024:86-101
pubmed: 15265775
J Biol Chem. 2001 Nov 16;276(46):42714-21
pubmed: 11555652
Cell Death Differ. 2007 Dec;14(12):2085-94
pubmed: 17932503
Cell Mol Life Sci. 2017 Jun;74(12):2217-2228
pubmed: 28168446
Cancer Res. 2019 Sep 1;79(17):4399-4411
pubmed: 31289134
Am J Surg Pathol. 2007 Nov;31(11):1645-52
pubmed: 18059220
Oral Oncol. 2017 Mar;66:38-45
pubmed: 28249646
Lancet Oncol. 2006 May;7(5):425-30
pubmed: 16648047
Proc Natl Acad Sci U S A. 2013 May 21;110(21):8708-13
pubmed: 23650397
Clin Cancer Res. 2013 Nov 15;19(22):6163-72
pubmed: 24016618
Steroids. 2010 Jan;75(1):1-12
pubmed: 19818358
Cancer Genet Cytogenet. 1998 Sep;105(2):160-3
pubmed: 9723034
Head Neck. 2016 Apr;38 Suppl 1:E1838-47
pubmed: 26699379
Oral Oncol. 2009 Nov;45(11):986-90
pubmed: 19574086
Head Neck Pathol. 2013 Jul;7 Suppl 1:S48-58
pubmed: 23821208
Cancer Res. 1985 Sep;45(9):4454-9
pubmed: 2862995
Int J Cancer. 2015 Feb 15;136(4):E27-38
pubmed: 25138562
Oral Oncol. 2017 Jun;69:108-114
pubmed: 28559013
Ann Otol Rhinol Laryngol. 1994 Mar;103(3):244-7
pubmed: 8122843
Head Neck. 2016 May;38(5):724-31
pubmed: 25522335
J Clin Oncol. 2006 Jun 10;24(17):2673-8
pubmed: 16763282
Cancer Res. 2011 Oct 15;71(20):6360-70
pubmed: 21868756
PLoS One. 2013;8(2):e54072
pubmed: 23457446
Endocr Rev. 2004 Apr;25(2):276-308
pubmed: 15082523
Elife. 2017 Sep 11;6:
pubmed: 28891793
Urology. 2002 Oct;60(4):553-61
pubmed: 12385906
Cancer Res. 2013 Mar 1;73(5):1570-80
pubmed: 23269278
Biochem J. 2002 Nov 1;367(Pt 3):907-11
pubmed: 12144530
Proc Natl Acad Sci U S A. 2004 Apr 6;101(14):4758-63
pubmed: 15037741
Cancer Lett. 2011 Mar 1;302(1):1-10
pubmed: 21078539
Mol Cell Endocrinol. 2018 May 5;466:38-50
pubmed: 28687451
Sci Transl Med. 2015 Sep 16;7(305):305ps19
pubmed: 26378243
Endocr Relat Cancer. 2015 Jun;22(3):R87-R106
pubmed: 25722318
J Clin Oncol. 2011 Jun 1;29(16):e473-6
pubmed: 21422415
Mol Cancer Ther. 2017 Aug;16(8):1680-1692
pubmed: 28428441
Steroids. 2002 May;67(6):529-34
pubmed: 11960631
Proc Natl Acad Sci U S A. 2015 Apr 28;112(17):5479-84
pubmed: 25847991
Clin Cancer Res. 2014 Dec 15;20(24):6570-81
pubmed: 25316813
Gynecol Oncol. 2017 Jul;146(1):153-160
pubmed: 28456378
Ann Oncol. 2018 Apr 1;29(4):979-984
pubmed: 29211833
Cancer Res. 2000 Feb 15;60(4):867-72
pubmed: 10706096
Clin Cancer Res. 2018 Jul 15;24(14):3433-3446
pubmed: 29636357
Cancer Cell. 2011 Jul 12;20(1):119-31
pubmed: 21741601
Cancer Biol Ther. 2014 Jun 1;15(6):678-82
pubmed: 24618694
Trends Pharmacol Sci. 2013 Sep;34(9):518-30
pubmed: 23953592
J Biol Chem. 2013 Aug 16;288(33):24020-34
pubmed: 23814048
Clin Cancer Res. 2016 Sep 15;22(18):4623-33
pubmed: 27103403
J Urol. 2003 Apr;169(4):1553-7
pubmed: 12629413
Cancer Cell. 2011 Aug 16;20(2):173-86
pubmed: 21840483
Arch Klin Exp Ohren Nasen Kehlkopfheilkd. 1968;192(1):100-5
pubmed: 4301301
Horm Cancer. 2014 Apr;5(2):72-89
pubmed: 24615402
Biochem Biophys Res Commun. 2009 Apr 17;381(4):671-5
pubmed: 19248771
Prog Brain Res. 2010;182:1-30
pubmed: 20541659
Adv Exp Med Biol. 2015;872:315-33
pubmed: 26216001
Clin Cancer Res. 2018 Feb 15;24(4):927-938
pubmed: 29158269
J Clin Oncol. 1996 Jun;14(6):1756-64
pubmed: 8656243
Cell. 2013 Dec 5;155(6):1309-22
pubmed: 24315100
J Mol Cell Biol. 2019 Dec 19;11(12):1042-1055
pubmed: 30726932
J Laryngol Otol. 2012 Jul;126 Suppl 2:S2-7
pubmed: 22495125
J Steroid Biochem Mol Biol. 2010 May 31;120(2-3):69-75
pubmed: 20346397
Gynecol Oncol. 2015 Sep;138(3):656-62
pubmed: 26115975

Auteurs

Yoshitsugu Mitani (Y)

Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Sue-Hwa Lin (SH)

Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Kristen B Pytynia (KB)

Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Renata Ferrarotto (R)

Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Adel K El-Naggar (AK)

Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas. anaggar@mdanderson.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH